Key Highlights

  • 22nd Century Group (NASDAQ:XXII) had 3,416,441 shares outstanding on Thursday, October 22, 2026 and no warrants, a small count for a quote under USD 0.15, and retail unit sales of its Pinnacle brands rose 161% between the second and third quarters.
  • Braiin Limited (NASDAQ:BRAI) paired its Force AI launch with three modules, AI Engage, AI Assist and AI Insight, whose performance figures are indicative results from selected deployments and not audited outcomes.
  • Senti Biosciences (NASDAQ:SNTI) holds two Nasdaq notices of Thursday, August 27, 2026: a bid price below USD 1.00 for 30 consecutive trading days and a stockholders' deficit of USD 3,401,000 at Tuesday, June 30, 2026.
  • Quantum Cyber N.V. (NASDAQ:QUCY) published audited Arcade statements in its filing of Monday, September 28, 2026 without a going-concern qualification, yet its presentation was not a research award or procurement commitment.

22nd Century Group (NASDAQ:XXII): a range expansion and a preliminary quarter

22nd Century Group (NASDAQ:XXII), a tobacco products company that markets the Pinnacle VLN and Pinnacle Pure brands, traded at USD 0.1424 in pre-market trading on Tuesday, October 27, 2026, a gain of 61.09% in the pre-market snapshot. Simple arithmetic on those two figures implies a prior close of about USD 0.0884. The company's release of Monday, October 26, 2026 expanded Pinnacle Pure to six variants, with shipments expected from December 2026, and followed the preliminary third-quarter results of Thursday, October 22, 2026. The move appears consistent with a reaction to these two announcements, although the company has not linked either to the share price.

The unaudited results show revenue from continuing operations of about USD 4.8 million for the quarter ended Wednesday, September 30, 2026, against USD 2.9 million in the second quarter, an increase of 66%. Gross profit was about USD 0.4 million, compared with a gross loss of USD 0.3 million, and the net loss was about USD 2.6 million, against USD 3.3 million. Cash fell to USD 3.9 million from USD 6.1 million. The improving gross margin supplies the mechanism for the reaction, while the cash balance sets its limit, and the proposed nicotine standard of 0.70 mg/g has not been finalised.

Braiin Limited (NASDAQ:BRAI): a global product launch without earnings data

Braiin Limited (NASDAQ:BRAI), an Australian technology company that operates the RADIUS contact-centre platform, traded at USD 2.96 in pre-market trading on Tuesday, October 27, 2026, a gain of 39.39% in the pre-market snapshot. Simple arithmetic implies a prior close of about USD 2.12. The catalyst is the company's release of Monday, October 26, 2026, which announced that Force AI, a unified artificial intelligence layer for an expanded RADIUS platform, was available globally. The release is a product announcement and does not disclose a contract, a revenue forecast or any income statement data.

Its operating metric is that RADIUS handled more than 4.5 million customer interactions at 99.9% uptime in the twelve months ended Tuesday, March 31, 2026. The mechanism for the move is therefore product novelty and a thin float rather than a change in reported earnings. The bear reading is that no customer, price or revenue contribution has been disclosed and that competition comes from larger contact-centre software vendors. The next periodic report is listed in an earnings calendar for Monday, November 9, 2026, a date the company has not confirmed.

Senti Biosciences (NASDAQ:SNTI): a pending transaction and no dated announcement

Senti Biosciences (NASDAQ:SNTI), a clinical-stage cell and gene therapy company, traded at USD 0.2253 in pre-market trading on Tuesday, October 27, 2026, a gain of 28.67% in the pre-market snapshot. Simple arithmetic implies a prior close of about USD 0.1751. No company-specific announcement dated on or just before that day accompanied the move. The rise appears consistent with thin liquidity in a share priced far below USD 1.00 and with trading around a transaction announced on Wednesday, July 15, 2026, under which affiliates of Celadon, the largest investor, would acquire the Gene-Circuit pipeline, including SENTI-202, while stockholders would receive a contingent value right of up to USD 60 million over seven years.

The latest reported financials are dated. In the first-quarter results of Thursday, May 14, 2026, the company reported a net loss of USD 4.2 million, helped by a USD 6.9 million lease-modification gain, and cash of USD 8.9 million, against USD 16.4 million at year-end 2025. A preliminary proxy proposes a reverse share split, and a third tranche of USD 2.0 million of senior secured convertible notes was allowed on Tuesday, September 1, 2026. SENTI-202 holds FDA RMAT designation, but the right is payable only on milestones. Investors should watch the stockholder meeting, for which no date was given, and the bid price deadline of Tuesday, February 23, 2027.

Quantum Cyber N.V. (NASDAQ:QUCY): a presentation and a new facility

Quantum Cyber N.V. (NASDAQ:QUCY), an autonomous defence technology company that is building drone, quantum antenna and swarm software platforms, traded at USD 0.9691 in pre-market trading on Tuesday, October 27, 2026, a gain of 13.81% in the pre-market snapshot. The catalyst identified is a company release dated Monday, October 26, 2026, which stated that the company was invited to present its quantum antenna technology in New Haven, Connecticut on Friday, October 16, 2026, naming magnetic navigation as the first milestone of its commercial roadmap.

The preceding updates concern capacity rather than earnings. The company acquired its Bridgeport, Connecticut facility and related business for USD 4.18 million in cash on Thursday, July 16, 2026, and an 80-unit 3D printing drone production farm became operational on Monday, August 31, 2026. No revenue, net loss or cash figures were included, so the mechanism is narrative momentum in a thinly traded share. No contract has been announced, and the request for information of Friday, September 4, 2026 is a solicitation, not an order. No date was identified for the next periodic report.

Where Things Stand

The answer is that thin floats and product or deal announcements lifted all four names, but each reached its move by a different route. 22nd Century Group (NASDAQ:XXII) offered the most disclosure, with preliminary revenue of about USD 4.8 million, yet its USD 3.9 million cash balance caps the reading. Senti Biosciences (NASDAQ:SNTI) moved without a dated announcement, around a pending transaction. Quantum Cyber N.V. (NASDAQ:QUCY) moved on a presentation that the company itself described as unfunded.

The next catalysts are the regular session on Tuesday, October 27, 2026, the Braiin report listed for Monday, November 9, 2026 and the 22nd Century report due on or before Friday, November 13, 2026. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.